Immutep targets $100m for lung cancer drug trial tests
Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
IFT | Ann: Amended - IFT230 Maturity and Exchange for IFT350 | 31/05/24 | 0 | 98 | |||
|
|||||||
IFT | Ann: Amended - IFT230 Maturity and Exchange for IFT350 | 31/05/24 | 0 | 50 | |||
|
|||||||
IFT | Ann: Infratil Infrastructure Bond Exchange Offer opens | 31/05/24 | 0 | 61 | |||
|
|||||||
IFT | Ann: Quotation Notice - Infratil Limited ("IFT350") | 30/05/24 | 0 | 54 | |||
|
|||||||
IFT | Ann: Infratil Infrastructure Bond Interest Rate Set | 30/05/24 | 0 | 65 | |||
|
|||||||
IFT | Ann: Infratil Infrastructure Bond Firm Offer Closes | 30/05/24 | 0 | 38 | |||
|
|||||||
IFT | Ann: Infratil Limited IFT230 Maturity and Exchange for IFT350 | 29/05/24 | 0 | 34 | |||
|
|||||||
IFT | Ann: ASX Appendix 2A - Application for Quotation of Securities | 28/05/24 | 0 | 69 | |||
|
See All Discussions